Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 332.45M | 371.08M | 391.25M | 426.39M | 488.98M |
| Total Receivables | -- | 5.00M | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 10.43M | 9.98M | 9.02M | 13.23M | 14.82M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 342.88M | 386.07M | 400.27M | 439.62M | 503.81M |
|
|
|||||
| Total Current Assets | 342.88M | 386.07M | 400.27M | 439.62M | 503.81M |
| Net Property, Plant & Equipment | 35.17M | 37.23M | 38.42M | 38.81M | 40.41M |
| Long-term Investments | -- | -- | 3.74M | 3.74M | 3.74M |
| Goodwill | -- | -- | 3.74M | 3.74M | 3.74M |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 5.97M | 7.04M | 8.24M | 9.52M | 9.53M |
| Total Assets | 384.02M | 430.34M | 450.66M | 491.68M | 557.48M |
|
|
|||||
| Total Accounts Payable | 7.77M | 7.44M | 8.20M | 20.44M | 10.50M |
| Total Accrued Expenses | 38.15M | 87.50M | 43.71M | 43.12M | 41.15M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 3.51M | 3.07M | 2.81M | 2.71M | 2.74M |
| Total Finance Division Other Current Liabilities | -- | -- | 152.00K | 425.00K | 403.00K |
| Total Other Current Liabilities | -- | -- | 152.00K | 425.00K | 403.00K |
| Total Current Liabilities | 49.43M | 52.73M | 54.88M | 66.69M | 54.80M |
|
|
|||||
| Total Current Liabilities | 49.43M | 52.73M | 54.88M | 66.69M | 54.80M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 38.65M | 39.58M | 40.46M | 41.32M | 42.62M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 558.00K | 849.00K | 996.00K | 1.09M | 1.29M |
| Total Liabilities | 88.64M | 93.15M | 96.33M | 109.10M | 98.71M |
|
|
|||||
| Common Stock & APIC | 1.40B | 1.39B | 1.36B | 1.35B | 1.34B |
| Retained Earnings | -1.10B | -1.05B | -1.01B | -966.77M | -878.49M |
| Treasury Stock & Other | 358.00K | 558.00K | 1.59M | 140.00K | 773.00K |
| Total Common Equity | 295.38M | 337.19M | 354.33M | 382.58M | 458.77M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 295.38M | 337.19M | 354.33M | 382.58M | 458.77M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 295.38M | 337.19M | 354.33M | 382.58M | 458.77M |
|
|
|||||